MORPHINE JUNO morphine hydrochloride trihydrate 100 mg/5 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

morphine juno morphine hydrochloride trihydrate 100 mg/5 ml solution for injection ampoule

juno pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: dilute hydrochloric acid; water for injections - - short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. - symptomatic relief of severe and intractable pains in terminal cancer patients. - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Depixol 20mg/ml Solution for Injection Ireland - English - HPRA (Health Products Regulatory Authority)

depixol 20mg/ml solution for injection

lundbeck ( ireland ) limited - flupentixol decanoate - solution for injection - 20 milligram(s)/millilitre - thioxanthene derivatives; flupentixol

APOMORPHINE WOCKHARDT apomorphine hydrochloride hemihydrate 10 mg/mL solution for injection or infusion ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

apomorphine wockhardt apomorphine hydrochloride hemihydrate 10 mg/ml solution for injection or infusion ampoule

wockhardt bio pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium hydroxide; hydrochloric acid; water for injections - apomorphine wockhardt solution for injection or infusion is indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.

Hydromorphone Hydrochloride 20 mg/ml Solution for Injection / Concentrate for Solution for Infusion Ireland - English - HPRA (Health Products Regulatory Authority)

hydromorphone hydrochloride 20 mg/ml solution for injection / concentrate for solution for infusion

ethypharm - hydromorphone hydrochloride - solution for injection/infusion - 20 milligram(s)/millilitre - natural opium alkaloids; hydromorphone

OXYCODONE HCl 20 mg/2 mL MEDSURGE oxycodone hydrochloride 20 mg/2 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

oxycodone hcl 20 mg/2 ml medsurge oxycodone hydrochloride 20 mg/2 ml solution for injection ampoule

medsurge pharma pty ltd - oxycodone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium chloride; water for injections; sodium hydroxide; hydrochloric acid; sodium citrate dihydrate - oxycodone hcl medsurge solution for injection or infusion is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Hydromorphone hydrochloride 20 mg/ml solution for injection/infusion Ireland - English - HPRA (Health Products Regulatory Authority)

hydromorphone hydrochloride 20 mg/ml solution for injection/infusion

as kalceks - hydromorphone hydrochloride - solution for injection/infusion - hydromorphone

Morphine Juno New Zealand - English - Medsafe (Medicines Safety Authority)

morphine juno

juno pharmaceuticals nz limited - morphine hydrochloride trihydrate 10 mg/ml equivalent to morphine base 7.58 mg/ml - solution for injection - 10 mg/ml - active: morphine hydrochloride trihydrate 10 mg/ml equivalent to morphine base 7.58 mg/ml excipient: hydrochloric acid water for injection - morphine hydrochloride is indicated for: - the relief of moderate to severe pain not responsive to non-opioid analgesics - symptomatic relief of severe and intractable pains of various categories, in terminal cancer patients - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia

APO-go 20mg/2ml solution for injection ampoules United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

apo-go 20mg/2ml solution for injection ampoules

britannia pharmaceuticals ltd - apomorphine hydrochloride - solution for injection - 10mg/1ml

Morphine Sopharma 20mg/ml Solution for Injection Malta - English - Medicines Authority

morphine sopharma 20mg/ml solution for injection

sopharma ad 16 iliensko shosse street, 1220 sofia, bulgaria - morphine hydrochloride - solution for injection - morphine hydrochloride 20 milligram(s)/millilitre - analgesics

ROPIVACAINE KABI ropivacaine hydrochloride 20 mg/10 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

ropivacaine kabi ropivacaine hydrochloride 20 mg/10 ml solution for injection ampoule

fresenius kabi australia pty ltd - ropivacaine hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - surgical anaesthesia (adults and children over 12 years of age); epidural block for surgery including caesarean section; intrathecal anaesthesia; field block (minor nerve block and infiltration); major nerve block. analgesia (adults and children over 12 years of age); continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain; field block (minor nerve block and infiltration); continuous peripheral nerve block infusion or intermittent injections for post operative pain management; continuous wound infusion for postoperative pain management (adults only). analgesia (children aged 0 - 12 years); caudal epidural block in neonates (> 37 weeks gestation and over 2500 g weight), infants and children up to and including 12 years. continous epidural infusion in infants (> 30 days and over 2500 g weight) and children up to and including 12 years; peripheral nerve block in children aged 1 up to and including 12 years. for peri- and postoperative pain management. there are no safety or efficacy data to support the use of ropivacaine hydrochloride for analgesia for longer than 72 hours. (data for peripheral nerve block administered as a continuous peripheral infusion or intermittent injections and for continuous wound infusion support the use for up to 48 hours only).